NEW YORK (Reuters) - Pfizer Inc is seeking to reformulate its HIV drug to prevent the transmission of the virus through a partnership with a nonprofit group, The Wall Street Journal reported on Wednesday. The report said Pfizer will license Selzentry, its oral HIV medicine, to the International Partnership for Microbicides, which will try to turn it into a vaginal gel, ring, or film that prevents transmission of the virus.
